 Antibody validation is of utmost importance for the biotech industry and academic research.  Discussion on this topic was highlighted at the 8 th Alpbach Affinity Proteomics Workshop.  Despite the practical challenges of defining a universal standard, consensus is emerging in the community.  A set of 'Alpbach recommendations' was proposed to address antibody validation issues.
research and diagnostics is to be able to select "the correct reagent for a particular target for a specific application" [1] . Much of the discussion in recent years has centred around the frequent reports that many research antibodies fail to live up to expectations, e.g. by not recognising the protein they are supposed to, by recognising a different protein instead of, or in addition to, the desired target, or functioning in some applications but not others [2] . The Alpbach meeting was reminded at the outset (Mathias Uhlén, Stockholm) that the Human Protein Atlas (www.proteinatlas.org) [3] has examined some 55,000 polyclonal antibodies (pAbs) and 5,000 monoclonals (mAbs) and found that, although many were validated in western blotting, only about 50% worked satisfactorily in the applications and sample preparation conditions used to generate the Atlas (immunohistochemistry and immunocytochemistry) [4] . Such frequent reports of failings have created a degree of uncertainty and confusion around antibody reagents as well as documented errors in published work, e.g. [5] [6] [7] [8] [9] . As a result, regardless of arena and application, a tremendous antibodies in research can also be seen as part of a larger drive to enhance rigour, reliability and transparency of biomedical research in general [12] [13] [14] [15] [16] [17] [18] . The aim (applicable to validation)
is to ensure research reproducibility, with transparency as the means to achieve it.
Following in this journal issue, authored by Alpbach participants, the Discussion article by Simon Goodman [19] relates his vexed personal experience of using commercial antibody reagents and the complexities at different levels surrounding their fitness for purpose. He argues for a number of remedies, including greater use of recombinant antibodies, more transparency on the part of (certain) producers and ultimately preparedness of individual users to carry out their own validations in their technique of choice. Ulf Landegren and colleagues
[20] follow up with their thoughts on the importance of achieving detection specificity sufficient to measure very low concentrations of target proteins such as troponin and other leakage markers, and how this may be achieved by proper design of diagnostic assays. Considerations of specificity also permeate the other articles in this special issue.
Characterisation and validation of antibodies
Antibody characterisation and validation can be regarded as parallel requirements which go hand in hand in determining the properties governing the use of antibodies in different applications.
Characterisation encompasses the basic attributes which are the core information for any antibody, namely the nature of the antibody molecule and the specific preparation in which it
is being supplied (serum, purified IgG, affinity-purified, etc.), knowledge of its binding specificity (identity of the target recognised at both the whole molecule and epitope level), cross-reactivity (identity of non-target reactants and the extent of off-target binding), affinity binding constant (both equilibrium and kinetic parameters), the antibody sequence and ultimately its combining site structure when complexed with the target. Typical characterisation methods include enzyme-linked immunosorbent assays (ELISA, target reactivity), surface plasmon resonance (SPR, affinity determination), peptide arrays (epitope mapping), protein arrays (specificity screens), variable (V)-gene cloning (sequencing) and X-ray crystallography (native and complexed structure determinations).
Validation extends these properties to the criterion of 'suitability for particular applications', which in the case of antibodies are legion and include immunoprecipitation (IP), western blotting (WB), sandwich assays, immunohistochemistry (IHC), immunocytochemistry (ICC), flow cytometry, proximity ligation, intracellular and in vivo action, and many others [21] . On the face of it, the high failure rate among antibody reagents in these techniques may seem surprising: the major distinction between native, fixed and denatured protein structures is well known, requiring appropriate reagents for those categories, but within them a reliable outcome with a target-specific binder would, perhaps naïvely, be anticipated. If that were the case, only three types of test would be needed, IP, IHC/ICC and WB. However, applications are increasingly specialised so that other considerations (e.g. how exactly the sample is fixed or denatured, the composition and complexity of the sample, incubation conditions, etc.) can moderate antibody functionality [4, [22] [23] [24] ). Moreover, target proteins of the same primary sequence may exhibit subtle cell-or tissue-specific differences which can alter their conformations and their epitopes, such as post-translational modifications (PTMs, e.g. glycosylation, phosphorylation), interacting proteins, etc. As antibodies are themselves proteins, their conformational diversity and PTMs can also impact their binding characteristics [25] , whether produced recombinantly or from natural sources. Thus, specificity, the most familiar property of antibodies, and its thorough and exact delineation for every case, turns out to be a major part of the problem. Validation of specificity for the 'real world' applications in which it will be used, namely against the target expressed at endogenous levels in cells and tissues, is the ultimate consideration that, from a practical standpoint, exceeds simple characterisation performed against a single or set of purified or exogenously overexpressed targets.
We provide one example (Figure 1 ) of a dataset showing application-specific differences in validation of a sizeable collection of target-specific monoclonal antibodies (mAbs). In this case, [26] . These results underscore that distinct mAbs (or for that matter any other binder type) may be suitable for a particular assay, but unsuitable for another even highly related assay, and that validation needs to be performed for each intended purpose. They also speak to the need for transparent reporting of the exact nature of any prior antibody validation, enabling it to be thoughtfully evaluated in relation to the user's needs.
These issues are not restricted to antibodies but are equally applicable to non-antibody protein binding molecules, such as DARPins, aptamers, monobodies, affimers and other molecular entities [27] , all of which exert an effect through their ability to bind to a protein target.
Moreover, they hold true as much for binders made through recombinant technologies as for the classical pAbs and mAbs. Purified pAbs often have excellent monospecificity, especially when affinity purified, and in the Human Protein Atlas validation results for a large number are presented transparently. While in principle mAbs have the capacity to be more specific, they sometimes exhibit entirely unexpected strong cross-reactions, where an epitope other than that intended fortuitously interacts well with the combining site. Although this has the potential to be amplified in polyclonal preparations, in which the constituent antibodies could each exhibit distinct properties, cross-reactivity in a pAb may be diluted out in many cases by being a mixed population, while reactivity with the target is common to all its components. In some cases, mAb cross-reactivity has been analysed by X-ray crystallography; indeed, it is possible to select for useful bispecific interactions in the same combining site [28] . It is perhaps too early to understand fully the specificity characteristics of the non-antibody binders where a smaller range has been produced, but for which many of the same principles will likely hold.
The antibody validation problem
There is no one particular use of antibodies: they reach into every aspect of biological and biomedical research, and immunoassay methods of one form or another are commonplace in virtually every type of research project. Different techniques make their own distinct demands of antibody reagents, but with shared underlying principles, essentially of specificity, crossreactivity, affinity, functionality and having the right tool for the right job, all viewed in the context of how the antibody will be used, including details of sample preparation. While there will be instances of anticipated cross-reactivity, such as between different isoforms of the same protein, each containing the epitope, there is also the unpredictable cross-reactivity to User surveys can be useful in trying to define the level of concern for this problem across the research community. In one case [29] a survey highlighted an association between willingness to carry out in-house validations and number of years of research experience of the respondents, drawing the conclusion that young researchers often either lacked awareness of its importance or saw validation as an obstacle rather than a necessity in their own experimental work. The conclusion was that a focus on education and training of junior researchers is needed to make them aware of the issue and ensure they are prepared to make the effort to satisfy themselves that the reagents they use perform as intended.
Sample quality standards in the pre-analytical phase
A particular instance of the need for quality control standards in respect of the sample rather than the antibody applies in the initial phase of the analytical process, including sample collection, handling, labelling and storage, especially in the clinical field where it is of utmost importance to ensure that correct and reproducible results with antibody reagents are achieved. The pre-analytical phase is considered one of the most vulnerable parts of immunoassays in general, highlighting the need for harmonisation between different centres.
If a sample is not handled correctly at the beginning of the analytical process, all subsequent antibody validation approaches will be compromised [30] . This was illustrated at the Alpbach workshop in connection with the reverse phase protein array (RPPA) technology (KarlFriedrich Becker, Munich). RPPA may have an important clinical application for analysis of
signalling networks and protein biomarkers in cancer tissues, but only if it can be guaranteed that the sample collection procedure follows identical standards within different institutions, since differences in handling will potentially cause unpredictable changes in protein and phosphoprotein profiles [31, 32] . Similar considerations apply to the effect on plasma protein determinations of pre-analytical blood collection and handling procedures, with temperature and pre-centrifugation delay of the blood sample being critical factors [33] . Standardisation of pre-analytical procedures is also particularly relevant in personalised medicine applications, where fast and accurate results could make a significant difference in the treatment approach to be followed. The EU consortia SPIDIA and its follow-up SPIDIA4P have proposed a number of CEN (European Committee for Standardization) technical specifications and ISO (International Organization for Standardization) global standards that provide guidelines for standardisation in the pre-analytical phase. Several of these documents are already available, with more expected in the coming years [34] .
A range of solutions: agreeing validation guidelines
A number of initiatives have suggested broad guidelines for antibody validation as well as detailed context-dependent measures. Three active groups offering solutions which can be highlighted are The European Monoclonal Antibody Network (EuroMAbNet) [35] , the
International Working Group on Antibody Validation (IWGAV) [1] and the Global Biological
Standards Institute (GBSI) [36] .
EuroMAbNet (www.euromabnet.com), comprising a network of well experienced academic laboratories engaged in mAb production, provide in their 'practical guide' [35] a very useful introduction to manoeuvring through the antibody jungle, tackling the validation issue stepwise from the ground up. Their article offers much helpful advice on, among others, obtaining background information on immunogen selection and design, the choice of antibody types in relation to envisaged techniques, finding highly rated suppliers and features of different databases. The point that the onus for validation is on the user is made repeatedly and is coupled with a set of criteria and instructions for researchers to use in-house for each antibody, tailored to the identity of the antigen and the demands of the technique to be used. The importance of confirming reactivity with the endogenous antigen is emphasised, an aspect now increasingly being confirmed with gene edited cell lines or knockout animal models.
A major contribution to bringing validation methods fully up to date has been made by the IWGAV in defining five sets of criteria or "validation pillars", making use of cutting edge developments in genomics and proteomics [1] . The approach is to seek correlations between editors and others advocating training, and the organisers went to some lengths to encourage audience engagement. Breakout sessions with working groups focused on developing certification standards for specific applications, including WB, IHC, IP and sandwich assays, were followed by electronic polling sessions which sought to come to consensus on their recommendations. This resembled the survey approach (above), but on-the-spot consensus proved quite difficult to reach, with strong voices counter to almost any approach proposed.
Consequently, it was deemed that further deliberations among working groups and selected panels would be needed. In the meantime, the outcome of the meeting has been presented in the form of 'consensus principles' and an extended report [36] , largely based on the IWGAV methodology.
One problem encountered, which goes back to the variety of antibody applications, is the diversity of different criteria among groups of stakeholders. As an example, in IHC the needs for those in the clinical pathology arena are very different from those engaged in basic research, such that antibodies certified for one purpose would likely fail in the other, due to
dramatic differences in sample preparation in terms of fixation. Similar anomalies exist for other techniques.
A suggestion promoted at the Asilomar meeting was in favour of a 'pick the winner' strategy with a scoring system for each antibody measured against a predefined set of rules and ultimately each antibody listed in catalogues or databases according to its score [36, 37] .
"Workshop attendees generally agreed that a system for scoring of antibodies for their overall quality and performance, and individual characteristics would be useful" [36] . This is a point of contrast with the IWGAV and EuroMAbNet approach of defining good quality antibodies through formal assessment criteria, with each antibody classified according to whether or not it fulfils the relevant criteria. The design of a universal scoring system raises questions of objectivity, scope, value and implementation, and the concept is likely to prove controversial, although even a compilation of the criteria used to validate individual antibodies would be valuable.
Minimal information initiative: MIAPAR
Reporting guidelines for unambiguously describing an antibody or other binder in its functional context, setting out the information required and a format for reporting, were provided a few years ago in the 'minimal information' style as MIAPAR or 'Minimal Information about a Protein Affinity Reagent' [38] , developed within the EU ProteomeBinders project [39] . "The key principle in MIAPAR is that an affinity binder is designed/developed to recognise a target, and unambiguous description of the binder requires description of its design/development, production, and evaluation as a molecular tool." [40] . In parallel, ProteomeBinders also proposed a Proteomics Standard Initiative for Protein Affinity Reagents (PSI-PAR) as a global community standard format for the representation and exchange of protein affinity reagent data [41] . The aim of MIAPAR was to permit the reliable reporting and identification of affinity reagents, their targets and applications; in short, a complete description of the antibody as a molecular reagent. Thus, a MIAPAR reporting document would include details of the antibody's production, its characterisation features, the validations performed describing its use in applications, and experimental references. The reported information is structured so as to allow for entry into databases and enable useful querying and automated data analysis and could be used in commercial catalogues or public databases. Authors submitting a paper including a new antibody or other affinity reagent would be requested to complete a MIAPAR form requiring the information, while subsequent publications could reference the MIAPAR description. Thus far, the MIAPAR format and recommendations, as well as similar attempts to establish a uniform convention for antibodies and other affinity proteomics reagents, have
not been embraced by the community or publishers, and journals may be unwilling to impose a stringent requirement. Nevertheless, the MIAPAR criteria can provide a model and framework for eventual adoption by journals.
Databases
Antibody databases can make an important contribution to validation and provide users with comparisons and recommendations. This is particularly important where, as frequently arises, researchers can choose between a large number of alternative antibodies for the proteins they study and require, as much as possible, some objective means to select the best products for their particular use. Two which were highlighted at Alpbach were CiteAb (www. 
Alpbach panel discussion
The antibody validation debate was continued at the 8th Alpbach workshop with a panel comprising academic researchers, publishers and commercial providers.* The panel was also invited to speculate on the future of antibodies. The following summarises points made in the discussion.
Validation principles
 While producers have a responsibility to provide as much detail on the origin and evaluation of their products as possible, including what has and has not been tested, as well
as on the precise nature of the product provided, ultimately the onus is on the user to ensure the required validation has been performed.
The now widely held view was affirmed that antibody specificity is context-dependent and that antibodies can only be properly validated in the application techniques and under the conditions in which they will ultimately be used. Validation should use the most modern technology available and be described in transparent detail (Mathias Uhlén, Stockholm). It should be noted that the conditions of an application assay will affect the properties of both the target and the antibody. 

Given that researchers still buy many poor quality antibodies, the question is whether it is feasible to implement standardized testing of a very large number of reagents in a large number of companies, and whether this can be done at an acceptable cost.There was also scepticism over the possible grading of antibodies by a universal scoring system [36, 37] , which was regarded as potentially complicated and difficult to distil from large amounts of data.
The fact that the same antibody can often be obtained from different suppliers, using different identification codes, confounds good faith efforts to replicate results with two independent reagents, as well as wasting valuable time and resources for researchers comparing what appear to be independent antibodies, for specificity and efficacy in their experimental system, but which in reality are the same antibody from different sources. should be required by all journals, the vendor and catalogue number should always be reported for mAbs together with a lot number for pAbs. It would also be appropriate to introduce a section on validation of key reagents into the Methods and encourage inclusion of detailed protocols. However, it is difficult for journals to mandate validation information or for staff to check it.
Publication of antibody-based results and requirements of authors


Beyond the straightforward statement of supplier, batch, etc., the situation regarding publishing guidelines is complex. According to Natalie de Souza (Chief Editor, Nature Methods), while journals can support and promote reagent validation and sharing, it is questionable whether they can respond effectively to the challenge of changing author behaviour. Major journals have taken a strong lead in raising the problem and increasing awareness. They also have the leverage to insist on standards but, with so many disparate publications, enforcing such standards across the entire field will be difficult. Moreover, antibodies are not a clearly defined field in themselves, their use is diverse, and they have no single user community, presenting a challenge of implementation of uniform standards. There is also the matter of limited editorial resources, so that where journals do request specific information and references, the rules are not strictly enforced. Until validation guidelines are agreed within the community, mandating inclusion of specific validation steps is unlikely.
The issue of limited editorial resources was also made by Janice Reichert (The Antibody Society, Editor in Chief of mAbs) who pointed out that, while mAbs (the journal), in common with other journals, requires as a minimum basic vendor information including lot numbers, any more advanced publication standards introduced for antibody validation must also be practical. She suggested that author checklists could be introduced, which would first require agreement on establishing the criteria and secondly place extra work on editorial staff and reviewers in going over the checklist data. The introduction of checklists could also have an educational effect on authors in alerting them to the issue.
There is also a burden on reviewers and, as cross-reactive antibodies may yield incorrect results, it is reasonable to ask what type of evidence they should request to confirm results and to what extent researchers can cite manufacturer testing. The question was posed by Fridtjof Lund-Johansen (Oslo), who also asked whether criteria need to be uniform for all results or just for those that are used to support the main conclusion. In reply, Natalie de Souza (Nature Methods) pointed out that editorial judgement will be needed, according to the importance of the antibody to the particular work. At one extreme, the antibody may be a new reagent and central to the conclusions of the study, in which case validation should be part of the paper. At the other extreme, the use of a particular antibody is peripheral to the main story, is of commercial origin and already well-documented in the literature, in which case simply reporting the details of the commercial product could be sufficient. It is also appropriate to ask reviewers with appropriate expertise to check the information on reagents, similar to what is done with statistics.
According to Lynn Sherrer (Elsevier, publisher of New Biotechnology), although there are time constraints in the publishing process and enforcement will not be easy, if publishers adopt reasonable standards that are mandatory, with feedback from the stakeholders, authors will adapt to them. Notwithstanding the concern that some may decide not to publish in a journal that has stringent standards for open data and transparency, most would continue to try to publish in high-impact journals. It is also an onus on the research community to become engaged when their members do not provide full and appropriate information and to be proactive in using feedback mechanisms to report and question reproducibility. RRIDs, most of these publications containing references to antibodies as well as other research resources for which RRIDs have been generated (mouse strains, software, etc.).
Currently PLOS requests but does not mandate RRIDs [45] , but since uptake to date is low, the possibility of mandating is under consideration. Cell Press is another publisher advocating the inclusion of RRIDs in manuscripts (https://www.cell.com/rrid). However, it remains the case that acceptance of, and adherence to, any universal system of transparent antibody documentation and reporting has not yet been accomplished.
The future binder landscape
Recombinants or more of the same?
A major area of recent discussion has been the benefits, over standard pAb and mAb reagents, of using antibodies and other binders produced by recombinant technologies, or by conventional means and then converted into recombinant form [46, 47] . This potentially their inherent properties will remain constant. In time, using an unsequenced antibody would be viewed as unacceptable as using an unsequenced plasmid. Indeed several companies are moving to position themselves in the recombinant antibody arena. In the long run, recombinants may not be cheaper, will still require the same level of validation, and some customers will prefer the familiarity of pAbs and mAbs; nevertheless they will enable improved reproducibility and consistency and will extend the possibilities available to researchers.
Assays using more than one binder
It is often pointed out that pairwise binding of affinity reagents greatly augments specificity over what can be achieved with single binders (Ulf Landegren, Uppsala). This goes back to the familiar sandwich assay which uses two binders against different epitopes for capture and detection; the same principle is employed in the in situ and solid phase proximity ligation assays invented by Landegren and colleagues [49] and can be expanded even further to three binders in a novel format [50, 51] . Employing the principle that the performance of affinity reagents needs to be measured in the contexts in which they are intended to be used means that binders intended to be applied in pairs should be evaluated as such both in solution and in situ. Hence ensuring distinct epitope recognition (absence of inter-antibody competition) becomes critical.
Large scale protein readouts
While the cost of DNA analyses (e.g. single nucleotide polymorphism identification) has decreased by orders of magnitude, this trend is much less evident in protein determinations. Implementation of such large-scale protein analyses will have a significant impact on disease prevention, diagnostics, drug development and selection, and 'wellness' monitoring (see also [20] for further discussion of these issues).
Alpbach recommendations
While establishing a single set of universal standards or guidelines was not a goal of this workshop, a set of overall recommendations emerged from the panel discussion (see Box).
They are not intended to be and assuredly will not be the final word on this subject and the debate over the best way to validate and report reagent antibodies will continue. In fact, future 
